Laboratory Investments
CDC invests in HIV, viral hepatitis, STI, and tuberculosis (TB) laboratories, which work around the clock to protect the health of all Americans. In FY 2017, CDC’s investments in laboratory services for HIV/AIDS Prevention and Research, Viral Hepatitis, STI, and TB Prevention was approximately $25 million. Using the most advanced technologies – some of which are only available in CDC laboratories – CDC accomplishes the following:
- assists state and local health departments in disease identification
- aids in outbreak detection
- improves disease diagnoses
- creates and tests new therapies
- develops technologies to monitor disease and antibiotic resistance
- models prevention strategies to guide clinical trials and recommendations
- increases quality and efficiency by researching, evaluating, and adopting new technologies that are better, faster, and cheaper
Learn More about CDC's Laboratory Investments
- CDC’s HIV, Viral Hepatitis, STD, and Tuberculosis Laboratories: At-A-Glance (infographic)
- CDC’s investments in Advanced Molecular Detection related to hepatitis C, STI, and gonorrhea
- CDC’s investments in Antibiotic/Antimicrobial Resistance, including drug-resistant Neisseria gonorrhoeae, and drug-resistant tuberculosis
Page last reviewed: July 23, 2018